At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Longeveron Mesenchymal Stem Cells (LMSCs) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
In Brief
A Phase 2 clinical trial evaluating Longeveron Mesenchymal Stem Cells (LMSCs) and Placebo for Aging Frailty. Completed, enrolled 150 participants across 7 sites.
Detailed Summary
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging Frailty
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionSep 2021
TodayJul 2026
First PostedMay 30, 2017
Enrollment StartJul 6, 2017
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 9.1 years ago
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs)biological
Intravenously delivered
Placeboother
Intravenously delivered